Week in Review Alphamab Closes $100 Million Series A for Oncology Candidates

Week in Review: Alphamab Closes $100 Million Series A for Oncology Candidates

Deals and Financings

News and Analysis 

• WuXi Biologics broke ground on a 1.6 million square foot Shanghai innovation center that will integrate biologics discovery, development, clinical and commercial manufacturing;
• CASI Pharma, a US-China company, announced plans to build a global cGMP manufacturing facility in Wuxi, China to manufacture its 29 generic drugs;

Trials and Approvals

• Gilead Sciences announced China approval to market Vemlidy^® (tenofovir alafenamide), an oral treatment for hepatitis B.

Stock Symbols: (SHZ: 000963) (L: SPH) (NYSE: LLY) (HK: 1672) (NSDQ: BIIB) (HK: 2269) (NSDQ: CASI) (NSDQ: GILD)

Share this with colleagues:

More From BioPortfolio on "Week in Review: Alphamab Closes $100 Million Series A for Oncology Candidates"